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Purpose: Thrombolytic therapy is widely used in the treatment of peripheral arterial 
occlusion, but prospective, randomized comparisons with standard therapy remain few. A 
multicenter t ial ofthrombolysis orperipheral arterial surgery (TOPAS) was organized to 
compare critically the use of recombinant urokinase (rUK) or surgery for the initial 
treatment of acute lower-extremity ischemia. Phase I of the trial was designed as a 
dose-ranging trial to evaluate the safety and efficacy of three doses o f rUK in comparison 
with surgery. 
Methods: In a multicenter, prospective, double-blind comparison, 213 patients who had 
acute lower-extremity ischemia for 14 days or fewer were randomized to one of two 
groups. The first group received one of three dosages of rUK (catheter-directed at 2000, 
4000, or 6000 IU/min for 4 hours, then 2000 IU/min to a maximum of 48 hours). The 
second group underwent surgery. Successful thrombolysis was followed by surgical or 
endovascular interventions when anatomic lesions responsible for the occlusion were 
unmasked. Patients were followed-up for I year; data were evaluated on an intent-to-treat 
basis. 
Results: The 4000 IU/min rUK dosage was chosen as the most appropriate thrombolytic 
regimen because itmaximized lytic efficacy against the risk of bleeding. Complete ( > 95%) 
lysis ofthrombus was achieved in 71% of the 49 patients who were randomized to the 4000 
IU/min group, with a mean infusion time of 23 hours. In contrast, complete lysis was 
achieved in 67% of patients who received 2000 IU/min and in 60% of patients who 
received 6000 IU/min. Hemorrhagic complications occurred in 2% of the 4000 IU/min 
group versus 13% of the 2000 IU/min group (p = 0.05) and 16% of the 6000 IU/min 
group (p = 0.03). In a comparison of the 4000 IU/min group with the surgical group, the 
1-year mortality rate (14% vs 16%) or amputation-free survival rate (75% vs 65%) did not 
differ significantly. The frequency and magnitude of surgery in the patients randomized 
to rUK were decreased (p < 0.001). 
Conclusion: The preliminary results uggest that an initial rUK dose of 4000 IU/min is safe 
and efficacious in the treatment of acute lower-extremity ischemia, rUK therapy is 
associated with limb salvage and patient survival rates similar to those achieved with 
surgery, concurrent with a reduced requirement for complex surgery after thrombolytic 
intervention. (J VASC SURG 1996;23:64-75.) 
Acute lower-extremity peripheral arterial occlu- 
sions are associated with significant costs to society in 
the form of protracted hospitalization, limb loss, and 
mortality. 1,2 The outcome of therapy is dependent on 
the severity of arterial compromise. The risks are 
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substantially greater in patients with acute limb- 
threatening ischemia than in patients with more 
chronic processes. 3'4 Restoration of arterial flow is 
the primary treatment goal and is accomplished 
through operative revascularization or pharmaco- 
logic dissolution ofthrombus. Thrombolytic therapy 
has been associated with varying rates of success 
depending on the characteristics of the patients 
studied and the method of investigation, s-8 
The study of thrombolysis or peripheral arterial 
surgery (TOPAS) was organized as a multicenter t ial 
to evaluate recombinant urokinase (rUK) throm- 
bolysis versus surgery in the initial treatment of 
patients with limb-threatening lower-extremity pe- 
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Table I. Eligibility criteria for randomization 
Inclusion criteria Exclusion criteria 
Acute lower-limb ischemia 
Less than 14-days duration 
Threatened (Class II 1~ severity 
Occlusion confirmed with arteriography 
Native artery or bypass graft 
Age older than or equal to 18 years 
Informed.consent by able patient or surrogate 
Eligible for both operative and thrombolytic intervention 
Profound ischemia with permanent motor paresis or sensory 
lOSS 
Uncontrolled hypertension, systolic -> 180, diastolic -> 110 
mm Hg 
Stroke within 6 months, transient ischemic attack within 2 
months 
Significant internal hemorrhage within 10 days 
Serious gastrointestinal hemorrhage within 14 days 
Biopsy of organs, puncture of incompressible v ssel within 14 
days 
Severe hepatic dysfunction 
Life expectancy less than 1 year 
Table II. Summary of numbers of patients randomized and patients treated per protocol 
2000 IU/min 4000 IU/min 6000 IU/min Surgery 
Patients randomized 
Patients withdrawing consent 
Entrance criteria not met 
Intervening medical event 
Other protocol variations 
Patients treated per protocol 
48 52 55 58 
0 1 0 3 
0 1 0 0 
2 0 2 0 
1 1 3 1 
45 49 50 54 
ripheral arterial occlusion. The study was divided into 
two phases; phase I was a double-blind dose-ranging 
study designed to evaluate three doses of rUK or 
surgery, and phase II was a direct comparison of the 
"best" rUK dose and surgery. As such, the aim of 
phase I was to use the primary endpoint of arterio- 
graphic dissolution ofthrombus to choose asafe and 
efficient rUK regimen. The aim of phase II was to 
quantify the benefits of surgery and thrombolysis 
with limb loss and mortality as the primary outcome 
measures. We report he results of the TOPAS phase 
I trial. 
METHODS 
The primary objective of phase I of the TOPAS 
trial was to compare the safety and efficacy of three 
intraarterial dosages of a recombinant urokinase 
(ABT-120, Abbott Laboratories, North Chicago, 
Ill.) versus urgery as the initial therapy for the treat- 
ment of limb-threatening lower-extremity peripheral 
arterial occlusion. Between February 26, 1993, and 
August 16, 1993, 67 U.S. and 5 Canadian investiga- 
tors in 79 participating clinical centers enrolled 213 
patients into the study. The clinical experience ofthe 
surgeons and angiographers were critically evaluated 
by members of the executive committee, and indi- 
viduals were excluded from participation if previous 
thrombolytic and operative xpertise were deemed 
inadequate. Patients were followed-up for 12 months 
after andomization. 
Study Drug. rUK, a glycoprotein of 48,000 d 
composed of two polypeptide chains connected 
through a single disulfide bond, is a proteolytic 
enzyme that specifically catalyzes the cleavage of a 
unique peptide bond within the inert plasminogen 
molecule and converts it to the active enzyme 
plasmin. The agent is a high-molecular weight 
analogue of the clinically available 32,000-d uroki- 
nase produced from tissue culture of human kidney 
cells (Abbokinase, Abbott Laboratories). rUK was 
produced with genetically engineered mouse cells, 
which were purified from the culture medium 
through aseries of chromatographic steps carried out 
in aqueous solution. The lyophilized therapeutic 
product was reconstituted with sterile water for 
injection. More than 90% of rUK was in the 
high-molecular weight form, with a specific activity 
of approximately 170,000 IU/mg as measured by 
clot lysis assay. 9 The half-life ofrUK was shown to be 
7 minutes in pharmacokinetic studies performed in 
monkeys. 
Patient Eligibility. Eligible patients included 
those with acute lower-extremity peripheral arterial 
occlusion that meet he criteria for class II (reversible 
limb-threatening) ischemia s defined by the Society 
for Vascular Surgery/International Society for Car- 
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Table III. Severity ranking of surgical 
procedures and death 
Death 
Above knee amputation 
Below knee amputation 
Major surgical procedures 
Insertion of a new bypass graft 
Replacement of an existing bypass graft 
Excision or repair of an aneurysm 
Moderate surgical procedures 













Medical treatment alone 
Initial thrombolytic administration 
Subsequent thrombolytic therapy 
Presented in order of decreasing severity. 
diovascular Surgery.I~ Symptoms were required to be 
less than 14 days in duration. Patients with throm- 
botic or embolic auses were eligible, as were patients 
with native artery or bypass graft involvement. 
Thromboses and embolic auses were defined on the 
basis of the clinical setting and the initial arterio- 
graphic appearance. Patients were excluded when a 
contraindication to surgical or thrombolytic therapy 
was present. Additional inclusion and exclusion 
criteria are listed in Table I. 
Randomization. Patients were assigned to a 
treatment group by a centralized randomization cen- 
ter, contacted at the time of patient enrollment via 
telephone. The randomization process was stratified 
by whether the occlusion involved a native artery or 
bypass grail. Patients were randomized after the 
inclusion and exclusion criteria were met, informed 
consent was obtained, a diagnostic arteriogram 
confirmed the presence of a native artery or bypass 
graft occlusion, and the investigator specified the 
planned treatment intervention in the event the 
patient was assigned to surgical therapy. The number 
of patients randomized and the number of patients 
who actually received the randomized therapy per 
protocol are given in Table II. 
Baseline Investigations. A medical history was 
obtained from each patient, and a physical examina- 
tion was performed with measurement of the ankle- 
brachial pressure index. Baseline hematologic and 
clinical chemistry profiles were obtained, and a 
pregnancy test was performed in all women with 
reproductive potential. Blood was drawn into pre- 
pared collection vials and mailed to the Central 
Laboratory (Department of Hematology, University 
of Rochester) to be tested for fibrinogen, plasmino- 
gen, and et2-antiplasmin levels. 
Treatment. Aspirin (325 mg) was administered 
orally to each patient enrolled in the study immedi- 
ately after informed consent was obtained. Heparin 
therapy was begun after arterial cannulation for 
diagnostic arteriography and was continued in pa- 
tients who were assigned to the rUK therapy group, 
adjusting the heparin dose to maintain the activated 
partial thromboplastin time at a factor of 1.5 to 2.0 
over control. Heparin therapy was continued at the 
discretion of the attending physician in the patients 
who were assigned to operative therapy. The three 
rUK treatment protocols differed in the rate of 
administration during the initial 4-hour infusion 
period: 2000 IU/min, 4000 IU/min, or 6000 
IU/min. Thereafter, administration was fixed at a rate 
of 2000 IU/min in all three groups, rUK infusions 
were terminated when complete lysis was achieved, 
when complications occurred, or after 48 hours of 
therapy. Successful rUK therapy was followed by 
surgical or endovascular interventions when a lesion 
was unmasked that was deemed responsible for the 
occlusive process. Warfarin therapy was begun in 
patients who required prosthetic bypass grafts to 
infrapopliteal rteries, in patients with occlusions of 
embolic ause, and in patients with presumed hyper- 
coagulable syndromes. 
Outcome Measures. Arteriography was repeated 
after 4 hours of rUK infusion in the thrombolytic 
groups. Follow-up arteriograms were obtained at the 
discretion of the investigator and at the completion of 
thrombolytic therapy. Central Laboratory fibrino- 
gen, plasminogen, and ~2-antiplasmin determina- 
tions were made at 4 and 48 hours of therapy, as well 
as at 8 and 24 hours if the rUK infusion was still in 
progress. Ankle-brachial pressure indices were mea- 
sured immediately before ach arteriogram and at 72 
hours in the patients who were randomized to rUK, 
and at 24, 48, and 72 hours in the patients who were 
randomized to surgery. Patient follow-up examina- 
tions were performed 30 days, 6 months, and i year 
after randomization. Ankle-brachial indices were 
repeated at 30 days, 6 months, and 1 year of 
follow-up. 
Arterial recanalization and the extent of clot lysis 
(complete vs incomplete) on the 4-hour arteriogram 
were the primary endpoints in determining the thera- 
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Table IV. Baseline characteristics of patients randomized to rUK and surgery 
2000 IU/min 4000 IU/min 6000 IU/min Surgery p 
Age (mean) 66.2 -+ 1.9 62.2 + 1.8 62.5 -+ 1.8 66.5 + 1.8 0.182 
Sex (percent male) 70.7% 74.4% 76.1% 62.2% 0.476 
Medical illnesses 
Cerebrovascular disease 14.6% 20.9% 13.0% 13.3% 0.904 
Malignancy 12.2% 11.6% 15.2% 8.9% 0.847 
Hypercholesterolemia 22.5% 30.2% 30.4% 34.1% 0.707 
Hypertension 48.8% 60.5% 58.7% 73.3% 0.134 
Diabetes 24.4% 41.9% 39.1% 40.0% 0.312. 
Coronary artery disease 43.9% 51.2% 37.0% 55.6% 0.308 
Congestive heart failure 14.6% 14,0% 15.2% 17.8% 0.975 
Tobacco history 75.6% 83.7% 87.0% 71.1% 0.229 
Type of  occlusion 
Native artery 39.6% 36.5% 45.5% 37.9% 0.794 
Bypass graft 60.4% 63.5% 54.5% 62.1% 0.794 
Thrombosis 89.6% 86.3% 89.1% 82.8% 0.732 
Embolism 10.4% 13.7% 10.9% 17.2% 0.732 
Duration of  process (days) 4.3 + 0.6 4.0 _+ 0.6 3.8 + 0.5 4.4 -+ 0.5 0.863 
Ankle-brachial index 0.14 + 0.04 0.13 +_ 0.04 0.20 -+ 0.03 0.21 + 0.04 0.278 
Length of  occlusion (cm) 34.8 -+ 3.6 38.3 + 3.5 31.7 - 3.4 33.5 _+ 3.3 0.594 
Signs and symptoms 
Rest pain 29.5% 34.6% 16.7% 25.9% 0.188 
Motor loss 29.5% 28.8% 35.9% 34.5% 0.871 
Sensory loss 56.8% 51.9% 55.6% 62.0% 0.825 
Muscle induration 11.4% 3.8% 9.4% 5.2% 0.443 
Ischemic ulceration 11.4% 7.7% 20.4% 17.2% 0.244 
Localized gangrene 4.5% 0 7.4% 3.4% 0.237 
Table V. Technical parameters elated to rUK infusion 
2000 IU/min 4000 IU/min 6000 IU/min Operation 
Catheter into clot* 39/47 (83.0%) 45/51 (88.2%) 42/53 (79.2%) - 
Guidewire traversal ~ 41/43 (95.3%) 42/44 (95.5%) 41/47 (87.2%) 22/24 (91.2%) 
Total rUK dose (106 IU) 2.7 -+ 0.22 3.2 -+ 0.22 3.5 -- 0.21 - 
Duration of  infusion (hr) 22.1 -+ 1.9 23.4-+ 1.8 22.3 _+ 1.8 - 
No statistically significant differences were found among treatment groups in any of  the categories evaluated. 
~Specified by number of  successful cannulations/guidewire passes over number of  attempts. 
Table VI. Changes in hematologic parameters from pretreatment to 4 hours after the onset of 
thrombolytic infusion 
Fibrinogen Plasminogen a2-antiplasmin 
rUK dose 
2000 IU/min - 12.3% -4 .2% - 31.7% 
4000 IU/min - 22.4% - 15.5% - 50.7% 
6000 IU/min - 27.2% - 26.3% - 64.3% 
P 
2000 vs 4000 0.003 0.078 < 0.001 
2000 vs 6000 < 0.001 < 0.001 < 0.001 
4000 vs 6000 0.468 0.076 0.055 
peutic efficacy of the various rUK dosages. The 
4-hour time point was chosen because the three rUK 
groups differed in the rate of infusion for the first 
4 hours only; thereafter, all patients received 2000 
IU/min. Secondary endpoints included (1) ampu- 
tation-free survival at 6 months after initiation of 
randomized therapy and (2) a composite in-hospital 
outcome index, defined as the most severe occurrence 
of ranked clinical procedures or events at the time of 
discharge from the initial hospitalization (Table III). 
The severity of intervention was also assessed in rela- 
tion to the intervention predicted by the investigator 
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Table VII. Summary of recanalization (antegrade flow) and complete ( > 95%) clot lysis at 4 hours 
and at the time of final arteriogram 
rUK dose (percent) p 
2000 IU/min 4000 IU/min 6000 IU/min 
(n = 4.5) (n = 49) (n = 50) 2 vs 4 ~ 2 vs 6* 4 vs 6 ~ 
4-Hour 
Recanalization 28 (62.2%) 
>95% Lysis 5 (11.1%) 
Final 
Recanalization 34 (75.6%) 
>95% Lysis 30 (66.7%) 
34 (69.4%) 30 (60.0%) 0.518 0.837 0.402 
11 (22.4%) 10 (20.0%) 0.176 0.272 0.810 
37 (75.5%) 38 (76.0%) 1.000 1.000 1.000 
35 (71.4%) 30 (60.0%) 0.660 0.530 0.291 
103 IU/min. 
Analysis includes only those patients who received randomized therapy. 
Table VIII .  Severe or life-threatening hemorrhagic complications in the rUK treatment groups 
rUK dose treatment group p 
2000 IU/min 4000 IU/min 6000 IU/min 
Site of bleeding (n = 45) (n = 49) (n = 50) 2000 vs 4000 2000 vs 6000 4000 vs 6000 
Catheter insertion site 4 (8.9%) 0 6 (12.0%) 0.0491- 0.744 0.027t 
Noninsertion site 3 (6.6%) 1 (2.0%) 3 (6.0%) 0.346 1.000 0.617 
All sites 6 (13.3%) 1 (2.0%) 8 (16.0%) 0.0525 0.778 0.031~ 
The frequency of hemorrhage at any site is not the simple sum of catheter and noninsertion sites because some patients bled at both 
locations. Analysis includes only patients who received the specified therapy. 
tSignificant at the 0.05 level. 
~Marginally significant (0.05 > p < 0.10). 
to be necessary if surgery was the only therapeutic 
option. The hematologic parameters that were evalu- 
ated included the fibrinogen, plasminogen, and a2- 
antiplasmin levels determined at randomization and 
at 4, 8, and 24 hours after initiation of rUK therapy. 
The frequency of treatment complications, pecifi- 
cally hemorrhage, was important in determining the 
most appropriate rUK dosage. Hemorrhage was de- 
fined by its locat ion-at the catheter insertion site or 
elsewhere. Hemorrhagic complications were defined 
as major when transfusion or surgery was required. 
Statistical Analysis. The sample size determina- 
tion of 50 patients per group was based on the 
assumption that a 25% intragroup difference in the 
primary endpoints of recanalization and complete 
clot lysis on the 4-hour arteriogram would be 
considered clinically important, with an 80% power 
and a one-sided c~ error of 0.05. Accordingly, a goal 
of 200 patients was set for the total phase I 
enrollment. 
All analyses were performed with intent-to-treat 
data. Pearson X 2 tests were performed on categorical 
data. Fisher's exact test was used when the sample 
sizes were small. Analysis of variance was performed 
with the test statistics based on the type III sum of 
squares. Censored ata were analyzed with Kaplan- 
Meier methods. All statistical analyses were per- 
formed with SAS procedures (Version 6.09; SAS 
Institute; Cary, N.C.). Unless otherwise noted, 
significance was assumed when the two-tailedp value 
was less than 0.05. Normally distributed ata were 
expressed as the mean + SE of the mean. 
RESULTS 
The four treatment groups had similar demo- 
graphic criteria, duration of symptoms, and severity 
of ischemia (Table IV). Thrombotic processes out- 
numbered embolic events, and infrainguinal occlu- 
sions were more common than suprainguinal occlu- 
sions. Occluded suprainguinal grafts were all pros- 
thetic; occluded infrainguinal grafts were prosthetic 
in 81%, in situ saphenous vein in 10%, and reversed 
saphenous vein in 9%. No significant intergroup 
differences were found in the cause of the occlusion 
or the distribution of graft types. " 
Concurrent medical illnesses and risk factors 
occurred with comparable frequency in the treatment 
groups. The duration of symptoms averaged slightly 
greater than 4 days and did not differ between 
groups. The length of the occlusion averaged be- 
tween 30 cm and 40 cm, with a mean of 15 cm to 25 
cm for native arterial occlusions and 38 cm to 47 cm 
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Table IX. Summary of planned surgeries, documented before randomization and tabulated by 
treatment group 
Nonthrombolytic 2000 IU/min 4000 IU/min 6000 IU/min Surge~ 
option (n = 48) (n = 52) (n = 55) (n = 58) 
AIx)ve knee amputation I (2.1%) 0 0 1 (1.7%) 
Below kalee amputation 0 0 0 0 
Transmetatarsal amputation 0 0 0 0 
Insertion/revision bypass graft 18 (37.5%) 12 (23.1%) 20 (36.4%) 17 (29.3%) 
Endarterectomy 1 (2.1%) 0 1 (1.8%) 0 
Thrombectomy/embolectomy 28 (58.3%) 40 (76.9%) 33 (60.0%) 40 (69.0%) 
Other 0 0 1 (1.8%) 0 
Anal~is includes all patients randomized. 
Table X. Planned versus actual interventions for all randomized patients 
2000 IU/min 4000 IU/min 6000 IU/min Surgery 
(n = 48) (n = 52) (n = 55) (n = 58) 
Worse than plan 15 (31.3%) 16 (30.8%) 19 (34.5%) 22 (37.9%) 
Same as plan 7 (14.6%) 11 (21.2%) 10 (18.2%) 28 (48.3%) 
Better than plan 26 (54.2%)* 25 (48.1%) ~ 26 (47.3%) ~ 8 (13.8%) 
~p < 0.001 min vs operation, better versus ame or worse, dichotomized, Fisher's exact est. 
for bypass graft occlusions. It was possible to position 
the catheter into the substance of the thrombus in 
83% of the patients randomized to thrombolysis 
(Table V), a proportion that did not differ signifi- 
cantly between rUK groups. Guidewire traversat 
through the thrombus was achieved in 92% of the 
attempts with no significant differences between the 
rUK and operative groups. The mean duration of 
thrombolytic nfusion did not differ among the three 
rUK groups and averaged 22 to 24 hours. The total 
dose of administered rUK increased from 2.7 +_ 0.22 
million units in the 2000 IU/min group to 3.54 -+ 
0.21 million units in the 6000 IU/min group. 
Hematologic Parameters. The fibrinogen, plas- 
minogen, and ~2-antiplasmin levels fell during the 
infusion ofthrombolyric agent, and the magnitude of 
the change closely paralleled the dose of rUK (Table 
VI). Changes in fibrinogen level were lowest in the 
2000 IU/min rUK group, with a decrease of 12.3% 
over the first 4 hours of infusion. By contrast, the 
fibrinogen concentration fell an average of 22.4% in 
the 4000 IU/min group (p = 0.003 vs 2000 IU/min 
group) and 27.2% in the 6000 IU/min group 
(p > 0.001 vs 2000 IU/min group) over the same 
period. Intragroup differences in the plasminogen 
and ~x2-antiplasmin concentrations were similar, with 
significantly lower levels in the higher dose groups. 
Treatment Efficacy. No statistically significant 
differences were found in the rate of recanalization or
the frequency of complete clot lysis between the three 
rUK dose regimens (Table VII). When the 4-hour 
arteriogram was pcrformcd, rccanalization of the 
occluding thrombus was achieved in approximately 
two thirds of the patients. Complete clot lysis was 
observed in less than one fourth of the patients at thi~ 
point. By contrast, recanalization was present in 
approximately three fourths of the patients in each 
group when the final arteriogram was performed, 
with complete clot lysis in two thirds of the cases. 
When lyric efficacy in bypass graft versus native 
arterial occlusions was analyzed, the 2000 IU/min 
rUK dosage appeared to be the least effective regimen 
for bypass grafts (p = 0.014 vs 4000 IU/min, 
p - -0 .099  vs 6000 IU/min). Complete clot lysis 
(->95% by volumc) at 4 hours was observed in 
12.5% of grafts treated with 2000 IU/min rUK, 
versus 34.6% and 31.6% of the grafts treated with 
4000 and 6000 IU/min rUK, respectively. Lower- 
dose rUK therapy, however, appeared to be sufficient 
for lysis of native arterial occlusions, without signif- 
icant differences between the rUK groups (p = 
1.000). 
Treatment Complications. Severe or life-threat- 
ening hemorrhagic complications occurred least of- 
ten in the 4000 IU/min group, both at the site of 
catheter insertion and at other sites (Table VIII). No 
difference was found in the frequency of hemorrhagic 
complications between the 4000 IU/min rUK group 
and the operative group (p = 0.476). Blood trans- 
fusions were necessary in 39% of the rUK patients 
and 30% of operative patients, without significant 
differences between the groups. Intracranial hemor- 
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Table XI. Survival rates in the rUK and surgery treatment groups 
Treatment group 
2000 4000 6000 Surge~ 
In-hospital mortality 7.3% 0 6.5% 6.7% 
30 day survivalt 95.8 +_ 2.5% 100% 96.4 _+ 2.2% 94.8 -+ 2.8% 
6 month survivalt 87.3 _+ 4.8% 90.2 -+ 4.2% 92.7 _+ 3.5% 87.9 -+ 4.3% 
12 month survivalt 82.8 _+ 5.5% 86.1 _+ 4.9% 90.7 + 4.0% 84.3 _+ 4.8% 
*Marginally significant (p < 0.10) 
tKaplan-Meier methods. 
Table XII. Amputation-free survival rates in the rUK and surgery treatment groups 
Treatment group 
2000 4000 6000 Surgery 
In-hospital 82.9% 90.7% 89.1% 91.1% 
30 days* 79.2 -+ 5.9% 90.4 + 4.1% 87.3 +_ 4.5% 86.2 -+ 4.5% 
6 months* 66.3 + 6.9% 78.6 -+ 5.7% 79.8 _+ 5.4% 74.1 -+ 5.8% 
12 months* 57.5 -+ 7.2% 74.6 -+ 6.1% 72.0 _+ 6.2% 65.4 + 6.3% 
*Kaplan-Meier methods. 
rhage developed in three patients in the rUK groups 
(2.1%), one in the 2000 IU/min group (2.2%), and 
two in the 6000 IU/min group (4.0%). No instances 
o.f intracranial bleeding occurred in the 4000 IU/min 
group or the operative group. Rigors related to rUK 
infusion were uncommon, occurring in only one 
patient (0.7%). 
Thrombolytic and Operative Interventions. 
No differences were found in the frequencies of 
prerandomization-predicted nonthrombolytic op- 
tions in the four treatment groups (p = 0.525). The 
most common preoperative plan was the perfor- 
mance of a thromboembolectomy (Table IX). The 
actual procedures were less severe than the pre- 
dicted interventions in 77 (49.7%) of the rUK pa- 
tients, with no significant differences between dosage 
groups (Table X). In contrast, the actual procedures 
were of lesser magnitude than predicted in only 8 
(13.8%) of the patients randomized to surgery 
(p < 0.001). 
Clinical Outcome. The posttreatment ankle-bra- 
chial index rose in all groups (p < 0.001), with an 
average increment ranging from 0.37 ___ 0.06 in the 
6000 IU/min rUK group to 0.50 __+ 0.06 in the 
operative group. The increments inthe anlde-brachial 
index were statistically equivalent between treatment 
groups. The length of hospital stay after randomiza- 
tion was similar in the four treatment groups, with a 
median of 9 to 10 days and a mean of 12 to 15 days. 
The in-hospital survival rate appeared highest in 
the 4000 IU/min rUK group; no in-hospital deaths 
occurred in this group (p = 0.075 vs surgery, 
p = 0.074 vs other rUK groups; Table XI). Simi- 
larly, the 30-day survival rate appeared highest in the 
4000 IU/min group, a difference that approached 
but did not attain statistical significance when com- 
pared with patients randomized to surgery (p = 
0.062 vs surgery). These differences did not persist o 
the 6 or 12 month follow-up time points. 
No differences were found in the amputation-free 
survival rates among the four treatment groups 
(Table XII). By contrast, significant differences were 
found in amputation-free survival rates among the 
native arterial rUK stratification subgroups. The 
amputation-free survival rate in patients with native 
arterial occlusions appeared best at the higher rUK 
doses, with 68.4 + 10.7% and 83.2 - 7.7% of the 
patients urviving to 1 year without amputation in 
the 4000 IU/min and 6000 IU/min groups, respec- 
tively, compared with only 45.3 _+ 11.7% of the 
patients in the 2000 IU/min group (p = 0.145 vs the 
4000 IU/min group, p = 0.007 vs the 6000 IU/min 
group). The amputation-free survival rate of patients 
with bypass graft occlusions appeared equal in all 
three rUK groups. 
Significant differences were found in the in- 
hospital outcome index among the thrombolytic 
groups and the operative group (Table XIII). The 
severity of the required intervention was lower in 
patients randomized to rUK regardless of the dosage. 
Open surgical procedures were avoided in 45.8% of 
patients randomized to rUK therapy, (p < 0.001 
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Table XI. (cont'd) 
p Values among groups 
2000~Surgery 4000~Surgery 6000~Surgery 2000/4000 2000/6000 4000/6000 
0.813 0.075" 0.947 0.074* 0.864 0.075" 
0.788 0.062* 0.664 0.096* 0.873 0.097* 
0.924 0.700 0.394 0.647 0.373 0.656 
0.641 0.790 0.302 0.655 0.246 0.464 
Table XII. (cont'd) 
p Values among groups 
2000~Surgery 4000~Surgery 6000~Surgery 2000/4000 2000/6000 4000/6000 
0.607 0.227 0.315 0.291 0.405 0.806 
0.342 0.493 0.867 0.116 0.272 0.608 
0.383 0.579 0.471 0.168 0.123 0.878 
0.413 0.292 0.451 0.071" 0.128 0.764 
rUK groups vs surgery). These differences persisted 
to 1 year of follow-up, with significantly fewer open 
interventions in the rUK groups than in the operative 
group (Table XIV). The requirement for open 
surgery did not differ among individual rUK doses 
during the initial hospitalization rduring follow-up 
to ! year after randomization. 
DISCUSSION 
Phase I of the TOPAS trial was designed to 
compare three doses of rUK therapy and surgery in 
the treatment of acute lower-extremity peripheral 
arterial occlusion. The data suggested that the 4000 
IU/min dosage ofrUK was most appropriate because 
it offered an acceptable balance between throm- 
bolytic efficacy anti safety. The 4000 IU/min dosage 
appeared to be associated with a higher rate of 
recanalization a d complete clot lysis on the 4-hour 
arteriogram, although these differences did not attain 
statistical significance. A significantly ower incidence 
of hemorrhagic complications in the 4000 IU/min 
group was found when compared with the two other 
rUK doses, and no patient who received a dose of 
4000 IU/min experienced intracranial bleeding. 
These observations were only marginally significant, 
however, especially with regard to the higher ate of 
bleeding in the lowest dose group. The possibility 
that the bleeding differences represent a chance 
observation cannot be excluded. 
Thrombolysis with rUK was associated with a 
significant reduction i  the magnitude of the required 
therapeutic ntervention when compared with pa- 
tients randomized to surgery; open surgical proce- 
dures were avoided in approximately one half of the 
patients. This benefit persisted without he require- 
ment for surgical procedures in20% (2000 IU/min) 
to 33% (6000 IU/min group) of rUK treated 
patients at 1-year of follow-up. 
The secondary endpoints of survival and ampu- 
tation-free survival occurred with similar frequency 
in the thrombolytic and operative treatment groups. 
Although phase II of the TOPAS trial was directed at 
a critical comparison of limb salvage and survival, the 
preliminary phase I observations suggest that acute 
limb-threatening lower-extremity arterial occlusion 
can be treated safely and effectively with catheter- 
directed rUK thrombolysis. Similar morbidity and a 
reduced frequency and magnitude of required sur- 
gery can be expected. 
The treatment options for patients with limb- 
threatening peripheral arterial occlusion include im- 
mediate surgery, anticoagulation, or thrombolytic 
therapy. Historically, surgery was the first treatment 
mode to be used, but operative therapy has been 
associated with an unexpectedly high periopera- 
tive mortality rate in the setting of acute ischemia. 2"3 
The excessive risk of perioperative complications 
prompted Blaisdell et al) to recommend that anti- 
coagulant therapy be used in the setting of acute limb 
ischemia nd that surgical revascularization be with- 
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Table XIII. In-hospital outcome indices 
2000 IU/min 4000 IU/min 6000 IU/min Surgery 
Outcome ~ (n = 48) (n = 52) (n = 55) (n = 58) 
Death 3 (6.3%) 0 3 (5.5%) 3 (5.2%) 
Above knee amputation 4 (8.3%) 4 (7.7%) 4 (7.3%) 0 
Below knee amputation 2 (4.2%) 1 (1.9%) 0 1 (1.7%) 
Major surgical procedure 7 (14.6%) 14 (26.9%) 15 (27.3%) 22 (37.9%) 
Moderate surgical procedure 6 (12.5%) 3 (5.8%) 5 (9.1%) 12 (20.7%) 
Minor surgical procedure 5 (10.4%) 6 (11.5%) 2 (3.6%) 14 (24.1%) 
Endovascular procedure 14 (29.2%) 14 (26.9%) 8 (14.5%) 2 (3.4%) 
Medical treatment alone 7 (14.6%) 10 (19.2%) 18 (32.7%) 4 (6.9%) 
~The most severe clinical outcome reported for each patient. 
p values, ordinal ogistic regression: rUK 2000 vs 4000:p = 0.571; rUK 2000 vs 6000:p = 0.461; rUK 4000 vs 6000:p = 0.814; rUK 
2000 vs operation: p = 0.053; rUK 4000 vs operation: p = 0.015; rUK 6000 vs operation: p = 0.046. 
Table XIV. Outcome indices at 12 months of follow-up, data from Kaplan-Meier analyses 
Outcome ~ 2000 IU/min 4000 IU/min 6000 IU/min Surgery 
Death 17.2% 13.9% 9.3% 15.7% 
Above knee amputation 12.7% 9,7% 13.0% 12.0% 
Below knee amputation 12.6% 1,8% 5.7% 6.9% 
Major surgical procedure 18.9% 34.3% 30.3% 34.4% 
Moderate surgical procedure 10.3% 3.8% 5.5% 12.0% 
Minor surgical procedure 8.4% 10.1% 1.9% 13.8% 
Endovascular procedure 15.7% 11.0% 12.5% 1.8% 
Medical treatment alone 4.2% 15.4% 21.8% 3.4% 
~The most severe clinical outcome reported for each patient. 
p values, survival analysis methodology, differences in cumulative occurrence rate, requirement for open surgical intervention: rUK 2000 
vs 4000: p = 0.440; rUK 2000 vs 6000: p = 0.096; rUK 4000 vs 6000: p = 0.377; rUK 2000 vs operation: p = 0.023; rUK 4000 vs 
operation: p = 0.002; rUK 6000 vs operation: p < 0.001 rain. 
held until the patient had been adequately stabilized 
with intravenous high-dose heparin. Despite the 
observations of Blaisdell and colleagues, anticoagu- 
lant therapy was never widely implemented, primar- 
ily because of its inability to directly restore nutrient 
blood flow to the limb. 
Thrombolytic therapy offered a compromise be- 
tween surgery and anticoagulation a d provided the 
potential to restore arterial flow through mildly in- 
vasive techniques. Tillett et al.n were pioneers in 
thrombolytic nvestigation and reported their initial 
experience with 11 patients in 1955. Several years 
later, Cliffton and Grossi 12a3 successfully used a mix- 
ture of streptokinase and plasminogen and infused 
the agents through catheters positioned irectly into 
arterial thrombi. Subsequently, a large number of 
retrospective reports appeared inthe literature,S,6,~4~ 8 
but it was not until the 1990s that prospective, ran- 
domized trials were organized. 
Three randomized comparisons of thrombolysis 
and surgery in the treatment of peripheral arterial 
occlusion have been published. The first randomized 
trial to be reported took place in Sweden and 
compared recombinant tissue plasminogen activator 
with operative thrombectomy in the treatment of 
acute arterial occlusion) 9 Only 20 patients were 
studied, which precludes meaningful conclusions 
from the data. 
The second randomized study, the University of 
Rochester t ial, compared the primary endpoints of 
amputation and mortality in patients with acute 
ischemia of the extremity. 2~ The 114 patients in this 
series were equally allocated to tissue-culture uroki- 
nase and surgery groups. A benefit in patient survival ' 
was noticed in the thrombolytic group, with 1-year 
survival rates of 84% and 58% in the urokinase and 
surgery groups, respectively. The University of 
Rochester trial differed from the TOPAS trial with 
regard to the acuity of ischemia, which averaged less 
than 24 hours in the former and just over 4 days in 
the latter. The increased fragility of the patients in the 
Rochester t ial, manifested by a threefold increase in 
the in-hospital mortality rate when compared with 
the TOPAS patients, probably accounted for the 
observations. 
The third randomized trial, Surgery versus 
thrombolysis for ischemia of the lower extremity 
(STILE), compared the results of recombinant tissue 
IOURNAL OF VASCULAR SURGERY 
Volume 23, Number 1 Ouriel, Veith, and Sasahara 73 
plasminogen activator, urokinase, or immediate sur- 
gery in 393 patients with lower-extremity peripheral 
arterial occlusions. 4The data were similar in the two 
thrombolytic treatment groups, and the groups were 
pooled for purposes of analysis. Unfortunately tech- 
nical failures were frequent in the STILE trial. The 
catheter could not be placed into the occluding 
thrombus in 41% of  patients with occluded bypass 
grafts and 22% of patients with occluded native 
arteries. The STILE trial documented a decreased 
incidence of ongoing or recurrent ischemia in the 
patients randomized to surgery, but the 30-day 
clinical outcome was similar with regard to limb 
salvage and mortality rates. Although not entirely 
sound from a statistical standpoint, a subgroup 
analysis was performed in which patients were 
stratified on the basis of  the duration of symptoms. A 
lower death and amputation rate was found in the 
patients randomized to thrombolysis when symp- 
toms were of less than 14 days' duration. An 
increased death and amputation rate was found, 
however, in the thrombolytic patients with more 
than 14 days of symptoms. The STILE results were 
similar to the TOPAS phase I results with regard to 
reduction in planned revascularization procedure in 
the thrombolytic groups. This benefit was achieved 
without an increase in the rate of death or amputation 
when compared with surgery. 
In summary, the TOPAS phase I data suggest that 
an initial rUK dosage of 4000 IU/min is safe and 
efficacious in the treatment of acute lower-extremity 
arterial occlusion. Corroborating the data of previous 
randomized trials of surgical versus thrombolytic 
intervention, the TOPAS phase I results suggest hat 
thrombolysis is associated with a reduction in the 
requirement for open surgery without an increase in 
the risk of death or limb loss. Patients with acute 
limb-threatening native arterial or bypass graft oc- 
clusions may be treated safely with initial rUK 
thrombolysis; any unmasked lesions with an endo- 
vascular or surgical approach may be subsequently 
addressed. Phase II of  the TOPAS study is designed 
to directly compare the results of thrombolysjs and 
surgery with the clinically relevant endpoints of limb 
loss and mortality. 
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DISCUSSION 
Dr. Anthony D. Whittemore (Boston, Mass.). This 
study reports results from the Phase I trial, a trial that was 
designed to define the role of rUK in peripheral arterial 
occlusive disease. This first phase, as Dr. Ouriel pointed 
out, is primarily a dosing trial that pertains to the initial 4 
hours of therapy. It established the comparative safety and 
initial, and I emphasize initial, efficacy of clot lysis using the 
midrange dose of 4000 IU/min. 
As a member of the Steering Committee and one of the 
investigators, I had the opportunity to review the data as 
they emerged, and I certainly concur with the relative 
efficacy and safety of the 4000 IU/min dose range. What 
bothers me is the extension of the conclusions from this 
study into the Phase II trial, the results of which are still 
undergoing analysis. Could you explain the difference 
between this trial and the findings of your previous tudy 
from Rochester with regard to overall mortality rate and 
elaborate on why we were unable to show an advantage in
overall patient mortality rate? 
The second question stems from the somewhat arbi- 
trary ranking of the interventions according to relative 
severity. This ranking enerated a great deal of debate in the 
Steering Committee. For instance, no one would argue that 
an amputation is a more severe outcome and intervention 
than a simple thrombectomy or angioplasty. But there's 
room for debate with regard to the comparative s verity of 
a simple thrombectomy versus lytic therapy. For instance, 
I'd submit hat a simple surgical thrombectomy under local 
anesthesia nthe oPerating room with 2 days in the hospital 
is less, not more severe, than a 24-hour infusion of rUK, 
three angiograms, a higher transfusion requirement, an 
intensive care unit setting that requires one-to-one nursing, 
and a longer hospital stay, which was a mean of 10 days in 
this particular study. I wonder if the authors would 
comment on the specificity of this relative ranking scale. 
Finally, of the patients randomized to the lytic group, 
a guide wire traversed the occlusion in 80% or 85% of 
attempts; of these, only 60% achieved complete clot lysis. 
Thus 50% of the lytic patients ultimately required the 
procedure as planned. According to Table 12, 75% of those 
50% who were initially treated with rUK ultimately 
required surgery during the following year; in fact, 34% of 
both groups ultimately required a major surgical proce- 
dure. Because the initial planned procedure in the 77% of 
the rUK group was a simple thrombectomy, and because 
88% of them ultimately required surgery, 34% of which 
were ranked as major, would the authors help me 
understand the advantages of urokinase? 
Dr. Kenneth Ouriel. The first question was about he 
differences between what we found in an initial randomized 
study in Rochester and the TOPAS trial. The study that we 
perfbrmed in Rochester was smaller, but more importantly, 
it was different from the TOPAS trial with regard to the 
acuity of ischemia. In our initial trial in Rochester, the 
average duration of ischemia was less than 24 hours versus 
approximately 4 days or so in the TOPAS trial. The 
increased fragility of the Rochester patients was shown by 
a threefold increase in the in-hospital mortality rate when 
compared with the TOPAS trial, so I think we're dealing 
with different patients. The Rochester group was com- 
posed of what I would call hyperacute patients. The 
TOPAS group would be acute, and we might call the 
STILE trial more subacute or chronic. 
The ranking of severity of interventions was very 
difficult, and we had many conference calls across the 
United States and Canada trying to decide how we could 
rank these indices. I tried in the presentation today to limit 
those to only four different groups that I thought most of 
us could agree with: endovascular versus surgical versus 
amputation and finally death. I certainly would agree with 
your conclusions with regard to simple thrombectomies. 
That gets into the third question of what are the real 
advantages of thrombolytic therapy. I think wemay not be 
able to show mortality rate differences when we're looking 
at patients with 1 or 2 weeks of ischemia, and we may not 
be able to show amputation differences. But I think if we 
can save the patient from having surgery, many of the 
patients are interested inthat from an emotional standpoint 
even though that may not be something that we're all 
interested in. If we can avoid surgery with the same 
mortality rate and the same amputation rate, then we may 
have done some good with thrombolysis. 
Dr. Anthony J. Roon (Everett, Wash.). I have two 
questions: (1) when you say that this is limb-threatening 
ischemia, are you including patients who have no sensation 
or motion in their foot, and (2) can you comment on the 
cost of treatment for the two groups? In managed care 
patients, we've been avoiding thrombolysis ince it fre- 
quently ends up doubling the cost of hospitalization for our 
patients. 
Dr. Ourlel. We had patients who had decreased motor 
and sensory function; we even had a few patients who had 
absent motor and sensory function, but by and large, these 
were patients who did not have a contraindication to 
thrombolytic therapy and thus were deemed able to 
withstand several hours or even many hours before 
reperfusion could be established. 
In terms of the cost, I would be interested in seeing 
your cost data. You say that the patients on rUK have a 
hospitalization cost that is twice that of the operative 
patients. That's not our experience. We've looked at that in 
another series of patients and found again and again that 
the costs are basically about he same. I can't ell you costs 
in this study, but I can tell you that the length of hospital 
stay, which is probably the prime determinant of cost, was 
identical in the groups. 
Dr. Bruce D. Braithwaite (Gloucester, United King- 
dom). The British thrombolysis study group has details on 
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about 400 patients who received tissue plasminogen 
activator, and we've identified the risk factors for major 
hemorrhage as the presence of an arterial sheath, the dose 
of the agent, and the duration of the agent. In addition, 
we've just completed a randomized trial of a high-dose 
method of tissue plasminogen activator versus a low-dose 
method, and our median time to lysis is 4 hours. Could you 
give me information on the sizes of catheters that you used 
in your three groups and would you consider using a 
different agent, which in our experience seems to be safer 
with a much lower hemorrhagic rate? 
Dr. Ouriel. The choice of the catheter used was left up 
to the investigator, but a review of the data would show 
that most catheters were 5 Fr. Sheaths were used in a large 
number of cases. In terms of whether or not tissue 
plasminogen activator or another agent is better than rUK, 
we just don't have the data. We do not have a randomized 
study that compares tissue plasminogen activator with rUK 
other than STILE, and the conclusion of STILE was that 
those two agents were identical. I think if we look at the 
data from the myocardial infarction trials and the coronary 
occlusion trials, I would guess that tissue plasminogen 
activator, although quicker, is associated with a higher 
incidence ofintracranial b eeding, and for that reason we've 
been reluctant o use tissue plasminogen activator in 
patients with a high incidence ofcerebrovascular problems. 
Dr. Braithwaite. In our study of 400 patients, our 
cerebral bleeding rate is only 2%, which is similar to yours. 
Dr. Wil lard C. Johnson (Boston, Mass.). Do you have 
an explanation why this 4000 IU/min dose both causes less 
bleeding and gives better lysis? 
Dr. Ouriel. I don't know why 4000 IU/min was 
better. I will say that the study was double-blind with 
regard to the three dosages, and when we reviewed the 
data, we didn't see 2000, 4000, and 6000 IU/min, what we 
saw was basically A, B, and C. We picked the dosage that 
looked best and it turned out to be the 4000 IU/min 
dosage. Why that was the case? I think it's a complex 
paradigm. We may be using up more plasminogen with the 
higher doses or we may be infusing for slightly longer in 
some of the lower-dose patients. I don't really have the 
answer to that. 
Dr. David H. Porter (Boston, Mass.). Our patients 
are monitored uring their rUK infusions every 6 hours for 
hematocrit, partial thromboplastin time, and fibrinogen 
levels. I was wondering if in your study you ever saw the 
fibrinogen levels increase as opposed to the expected 
decrease? We've seen a fair number anecdotally and haven't 
really looked into this. 
Dr. Ouriel. Well, some patients do have an increase in 
fibrinogen on thrombolytic therapy, but with these rela- 
tively high doses that we're using, especially 4000 and 6000 
IU/min, in general the fibrinogen levels decrease, as 
illustrated in the graph that I presented. 
Dr. Kevin Burnand (London, United Kingdom). The 
cynic might say that the advantage of this method is it 
allows you to stay in bed and do your operation the next 
day. The other comment I have, to give us an indication of 
the severity of the ischemia of the leg, is how often have you 
had to do fasciotomies on these patients? 
Dr. Ouriel. I don't have exact numbers of the 
fasciotomies. Certainly fasciotomies were required. In this 
initial small series we found no difference in the require- 
ment for fasciotomy between the groups, but that's 
something that we can look at with the larger series, the 
Phase II data. 
